Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH | Q02127 | 1/20 | 0.34 |
| ▸ | LIPE | Q05469 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19403628 | 0.76 | DHODH (0.36) | DHODHSMN1; SMN2 | |
| SCHEMBL23370465 | 0.71 | SMN1; SMN2 (0.34) | DHODHLIPESMN1; SMN2 | |
| SCHEMBL21466985 | 0.71 | DHODH (0.34) | DHODHSMN1; SMN2 | |
| SCHEMBL19429595 | 0.71 | DHODH (0.34) | DHODHLIPESMN1; SMN2 | |
| SCHEMBL17792498 | 0.64 | DHODH (0.37) | DHODH | |
| SCHEMBL3529197 | 0.64 | HSD11B1 (0.40) | DHODHSMN1; SMN2 | |
| SCHEMBL19934961 | 0.62 | CYP1A2 (0.36) | DHODH | |
| SCHEMBL26340808 | 0.58 | POLB (0.32) | LIPE | |
| SCHEMBL14752127 | 0.58 | — | — | |
| SCHEMBL19040335 | 0.57 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210147430-A1 | PYRROLOTRIAZINE COMPOUNDS AS TAM INHIBITORS | INCYTE CORPORATION | 2021-05-20 | — | — | US | disclosed |
| US-10844069-B2 | Pyrrolotriazine compounds as TAM inhibitors | INCYTE CORPORATION (US) | 2020-11-24 | — | — | US | disclosed |
| US-20200131185-A1 | PYRROLOTRIAZINE COMPOUNDS AS TAM INHIBITORS | INCYTE CORPORATION | 2020-04-30 | — | — | US | disclosed |
| US-10442810-B2 | Pyrrolotriazine compounds as TAM inhibitors | INCYTE CORPORATION (US) | 2019-10-15 | — | — | US | disclosed |
| US-9981975-B2 | Pyrrolotriazine compounds as tam inhibitors | INCYTE CORPORATION (US) | 2018-05-29 | — | — | US | disclosed |
| US-9981975-B2 | Pyrrolotriazine compounds as tam inhibitors | INCYTE CORPORATION (US) | 2018-05-29 | — | — | US | disclosed |
| US-20170275290-A1 | PYRROLOTRIAZINE COMPOUNDS AS TAM INHIBITORS | INCYTE CORPORATION | 2017-09-28 | — | — | US | disclosed |
| US-20170275290-A1 | PYRROLOTRIAZINE COMPOUNDS AS TAM INHIBITORS | INCYTE CORPORATION | 2017-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210147430-A1 | PYRROLOTRIAZINE COMPOUNDS AS TAM INHIBITORS | MERTK, MAP3K15, MAP3K5 | DHODH 1622/4885LIPE 4031/4885SMN1; SMN2 4774/4885 |
| US-10844069-B2 | Pyrrolotriazine compounds as TAM inhibitors | MERTK, MAP3K15, MAP3K5 | DHODH 1622/4885LIPE 4031/4885SMN1; SMN2 4774/4885 |
| US-20170275290-A1 | PYRROLOTRIAZINE COMPOUNDS AS TAM INHIBITORS | MERTK, MAP3K15, MAP3K5 | DHODH 1622/4885LIPE 4031/4885SMN1; SMN2 4774/4885 |
| US-20200131185-A1 | PYRROLOTRIAZINE COMPOUNDS AS TAM INHIBITORS | MERTK, MAP3K15, MAP3K5 | DHODH 1622/4885LIPE 4031/4885SMN1; SMN2 4774/4885 |
| US-10442810-B2 | Pyrrolotriazine compounds as TAM inhibitors | MERTK, MAP3K15, MAP3K5 | DHODH 1622/4885LIPE 4031/4885SMN1; SMN2 4774/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.